Hepatitis C Virus Infection Clinical Trial
Official title:
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02487030 -
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 | |
| Active, not recruiting |
NCT05460130 -
Implementing HCV Treatment for High-risk Populations in Austin, Texas
|
N/A | |
| Completed |
NCT02220998 -
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
|
Phase 3 | |
| Terminated |
NCT01052090 -
Safety and Efficacy Study in Hepatitis C Patients With PHN121
|
Phase 1/Phase 2 | |
| Completed |
NCT02537379 -
Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
|
N/A | |
| Recruiting |
NCT04156945 -
Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men
|
N/A | |
| Terminated |
NCT02510300 -
A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
|
||
| Withdrawn |
NCT04309734 -
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04001608 -
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients
|
Phase 3 | |
| Completed |
NCT04112303 -
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
|
Phase 3 | |
| Completed |
NCT02251717 -
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection
|
Phase 2 | |
| Recruiting |
NCT05092074 -
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
|
||
| Recruiting |
NCT04005248 -
Prevalence of HCV in HIV-negative MSM
|
N/A | |
| Completed |
NCT02249182 -
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
|
Phase 2 | |
| Completed |
NCT02939989 -
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
|
Phase 3 | |
| Completed |
NCT01718145 -
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
|
Phase 3 | |
| Completed |
NCT01482611 -
A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382
|
Phase 1 | |
| Completed |
NCT00255177 -
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients
|
Phase 2 | |
| Terminated |
NCT02600351 -
Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
|
Phase 3 | |
| Completed |
NCT04980157 -
CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers
|